Rheology, Durability, and Mechanical Performance of Sustainable Self-Compacting Concrete With Metakaolin and Limestone Filler

Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG[Abstract] This study analyzed the performance of self-compacting concrete with a paste composition that includes limestone filler and metakaolin replacing cement to design binary (75% cement and 25% limestone filler) and ternary binders (60% cement, 25% limestone filler and 15% metakaolin). Furthermore, to analyze the effect of the solid volume fraction (volume of sand and coarse aggregate) on concrete rheology, the concretes were designed using four volumes of paste (350 l, 400 l, 450 l and 500 l). Rheological tests were performed at three resting times to measure the viscosity and yield stress over time. The results indicated that the viscosity decreased by 43.3% when the cement was replaced by limestone filler and increased by 73.1% when the cement was replaced by 15% metakaolin while maintaining the limestone filler. These values were obtained as 27.6% and 62.2%, respectively, when the yield stress was analyzed. In addition, the hardened properties (mechanical behavior and durability) were studied by measuring the strengths at 28 days, as well as the electrical resistivity and ultrasonic pulse velocity over time. In this case, at 28 days the use of binary binder reduces the strength and resistivity (about 20%) and the employment of ternary binder reduces strength (15%) while increases the resistivity up to the double (when compared to the 100 C concrete). Moreover, to measure the efficiency of the concrete, a material index was designed that considers the fresh behavior, mechanical performance, durability, cost, and environmental impact. Self-compacting concretes with ternary binders provided the highest indices. The use of alternative materials, particularly metakaolin has been proven to be a good option to enhance concrete sustainable performance.The study is part of two projects entitled: “Robust self-compacting recycled concretes: rheology in fresh state and mechanical properties (Ref: BIA2014-58063-R)” and “Sustainable High Performance Self-Compacting Concrete using low clinker cement, and integral curing and self-healing agents (HACCURACEM) (BIA2017-85657-R)” funded by MINECO. Moreover, this work was also made possible by the financial support of a pre-doctoral grant of MINECO (FPI 2015- ref BES-2015-071919) and two grants for international pre-doctoral stays: (a) FPI 2015 and (b) IACOBUS program for “Galicia–North of Portugal Euroregion

Comparing and Tuning Machine Learning Algorithms to Predict Type 2 Diabetes Mellitus

The main goals of this work is to study and compare machine learning algorithms to predict the development of type 2 diabetes mellitus. Four classifi cation algorithms have been considered, studying and comparing the accuracy of each one to predict the incidence of type 2 diabetes mellitus seven years in advance. Specifically, the techniques studied are: Decision Tree, Random Forest, kNN (k-Nearest Neighbors) and Neural Networks. The study not only involves the comparison among these techniques, but also, the tuning of the meta-parameters in each algorithm. The algorithms have been implemented using the language R. The data base used is obtained from the nation-wide cohort [email protected] study. The conclusions will include the accuracy of each algorithm and therefore the best technique for this problem. The best meta-parameters for each algorithm will be also provided.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tec

Influencia de las variaciones en los materiales sobre la reología de hormigones autocompactantes reciclados

[ES] Este trabajo se centra en el análisis de la influencia de las variaciones de materiales sobre el comportamiento reológico de los hormigones autocompactantes fabricados con árido grueso reciclado. Se diseña un hormigón autocompactante patrón y tres reciclados con porcentajes de sustitución del 20%, 50% y 100% en volumen. Asimismo, en cada una de estas mezclas se aplican variaciones en el contenido de agua, superplastificante y cemento para simular los errores que se producen en las plantas de fabricación: ± 3% en el agua, ± 5% en el superplastificante y ± 3% en el cemento. Todos los hormigones se estudian en estado fresco mediante los ensayos reológicos stress growth test y flow curve test. Mediante reógrafos se evalúan los cambios reológicos que los incrementos o decrementos de agua, superplastificante o cemento pueden ocasionar. Los resultados permiten estudiar a qué variación de material es más sensible un hormigón autocompactante reciclado (HACR) y qué porcentajes de árido reciclado sería más recomendable utilizar para obtener un hormigón robusto.Este estudio es parte de los proyectos (a) “Investigación industrial sobre Hormigones para un Mercado Sostenible (InHorMeS)” financiado por la Axencia Galega de Innovación (Ref: IN852A 2013/57); y (b) “Hormigones reciclados autocompactantes robustos: reología en estado fresco y propiedades mecánicas (HORREO)” financiado por el Ministerio de Economía y Competitividad (Ref: BIA2014-58063-R). Además, este trabajo fue posible gracias al apoyo de una beca predoctoral de la Xunta de Galicia (España).González Taboada, I.; González Fonteboa, B.; Martinez Abella, F.; Rojo López, G. (2018). Influencia de las variaciones en los materiales sobre la reología de hormigones autocompactantes reciclados. En HAC 2018. V Congreso Iberoamericano de hormigón autocompactable y hormigones especiales. Editorial Universitat Politècnica de València. 65-74. https://doi.org/10.4995/HAC2018.2018.6361OCS657

A school-based program implemented by community providers previously trained for the prevention of eating and weight-related problems in secondary-school adolescents : the MABIC study protocol

Background: The prevention of eating disorders and disordered eating are increasingly recognized as public health priorities. Challenges in this field included moving from efficacy to effectiveness and developing an integrated approach to the prevention of a broad spectrum of eating and weight-related problems. A previous efficacy trial indicated that a universal disordered eating prevention program, based on the social cognitive model, media literacy educational approach and cognitive dissonance theory, reduced risk factors for disordered eating, but it is unclear whether this program has effects under more real-world conditions. The main aim of this effectiveness trial protocol is to test whether this program has effects when incorporating an integrated approach to prevention and when previously-trained community providers implement the intervention. Methods/design: The research design involved a multi-center non-randomized controlled trial with baseline, post and 1-year follow-up measures. Six schools from the city of Sabadell (close to Barcelona) participated in the intervention group, and eleven schools from four towns neighboring Sabadell participated in the control group. A total of 174 girls and 180 boys in the intervention group, and 484 girls and 490 boys in the control group were registered in class lists prior to baseline. A total of 18 community providers, secondary-school class tutors, nurses from the Catalan Government's Health and School Program, and health promotion technicians from Sabadell City Council were trained and delivered the program. Shared risk factors of eating and weight-related problems were assessed as main measures. Discussion: It will be vital for progress in disordered eating prevention to conduct effectiveness trials, which test whether interventions are effective when delivered by community providers under ecologically valid conditions, as opposed to tightly controlled research trials. The MABIC project will provide new contributions in this transition from efficacy to effectiveness and new data about progress in the integrated approach to prevention. Pending the results, the effectiveness trial meets the effectiveness standards set down by the Society for Prevention Research. This study will provide new evidence to improve and enhance disordered eating prevention programs

Jardins per a la salut

Facultat de Farmàcia, Universitat de Barcelona. Ensenyament: Grau de Farmàcia. Assignatura: Botànica farmacèutica. Curs: 2014-2015. Coordinadors: Joan Simon, Cèsar Blanché i Maria Bosch.Els materials que aquí es presenten són el recull de les fitxes botàniques de 128 espècies presents en el Jardí Ferran Soldevila de l’Edifici Històric de la UB. Els treballs han estat realitzats manera individual per part dels estudiants dels grups M-3 i T-1 de l’assignatura Botànica Farmacèutica durant els mesos de febrer a maig del curs 2014-15 com a resultat final del Projecte d’Innovació Docent «Jardins per a la salut: aprenentatge servei a Botànica farmacèutica» (codi 2014PID-UB/054). Tots els treballs s’han dut a terme a través de la plataforma de GoogleDocs i han estat tutoritzats pels professors de l’assignatura. L’objectiu principal de l’activitat ha estat fomentar l’aprenentatge autònom i col·laboratiu en Botànica farmacèutica. També s’ha pretès motivar els estudiants a través del retorn de part del seu esforç a la societat a través d’una experiència d’Aprenentatge-Servei, deixant disponible finalment el treball dels estudiants per a poder ser consultable a través d’una Web pública amb la possibilitat de poder-ho fer in-situ en el propi jardí mitjançant codis QR amb un smartphone

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. Therefore, we aimed to generate a novel measure of disease progression and to identify genetic markers associated with this progression measure. Methods We generated a progression score on the basis of principal component analysis of prospectively acquired longitudinal changes in motor, cognitive, and imaging measures in the 218 indivduals in the TRACK-HD cohort of Huntington's disease gene mutation carriers (data collected 2008–11). We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of Huntington's disease mutation carriers (data collected 2003–13). We did a genome-wide association analyses in terms of progression for 216 TRACK-HD participants and 1773 REGISTRY participants, then a meta-analysis of these results was undertaken. Findings Longitudinal motor, cognitive, and imaging scores were correlated with each other in TRACK-HD participants, justifying use of a single, cross-domain measure of disease progression in both studies. The TRACK-HD and REGISTRY progression measures were correlated with each other (r=0·674), and with age at onset (TRACK-HD, r=0·315; REGISTRY, r=0·234). The meta-analysis of progression in TRACK-HD and REGISTRY gave a genome-wide significant signal (p=1·12 × 10−10) on chromosome 5 spanning three genes: MSH3, DHFR, and MTRNR2L2. The genes in this locus were associated with progression in TRACK-HD (MSH3 p=2·94 × 10−8 DHFR p=8·37 × 10−7 MTRNR2L2 p=2·15 × 10−9) and to a lesser extent in REGISTRY (MSH3 p=9·36 × 10−4 DHFR p=8·45 × 10−4 MTRNR2L2 p=1·20 × 10−3). The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis (p=1·58 × 10−8), and encodes an aminoacid change (Pro67Ala) in MSH3. In TRACK-HD, each copy of the minor allele at this SNP was associated with a 0·4 units per year (95% CI 0·16–0·66) reduction in the rate of change of the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score, and a reduction of 0·12 units per year (95% CI 0·06–0·18) in the rate of change of UHDRS Total Functional Capacity score. These associations remained significant after adjusting for age of onset. Interpretation The multidomain progression measure in TRACK-HD was associated with a functional variant that was genome-wide significant in our meta-analysis. The association in only 216 participants implies that the progression measure is a sensitive reflection of disease burden, that the effect size at this locus is large, or both. Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation

A first update on mapping the human genetic architecture of COVID-19

peer reviewe

Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes

Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson’s disease (PD) and Alzheimer’s disease (AD) versus controls. We demonstrate that the two diseases share the same protective association at the HLA locus. HLA-specific fine-mapping showed that hierarchical protective effects of HLA-DRB1*04 subtypes best accounted for the association, strongest with HLA-DRB1*04:04 and HLA-DRB1*04:07, and intermediary with HLA-DRB1*04:01 and HLA-DRB1*04:03. The same signal was associated with decreased neurofibrillary tangles in postmortem brains and was associated with reduced tau levels in cerebrospinal fluid and to a lower extent with increased Aβ42. Protective HLA-DRB1*04 subtypes strongly bound the aggregation-prone tau PHF6 sequence, however only when acetylated at a lysine (K311), a common posttranslational modification central to tau aggregation. An HLA-DRB1*04-mediated adaptive immune response decreases PD and AD risks, potentially by acting against tau, offering the possibility of therapeutic avenues

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570